Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies.
bone marrow
electrophoresis, capillary
immunofixation
in situ hybridization, fluorescence
monoclonal gammopathy of undetermined significance
multiple myeloma
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
27 11 2023
27 11 2023
Historique:
received:
30
03
2023
accepted:
29
05
2023
medline:
26
10
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Monoclonal gammopathies (MG) are characterized by the proliferation of plasma cells that produce identical abnormal immunoglobulins (intact or some of their subunits). This abnormal immunoglobulin component is called monoclonal protein (M-protein), and is considered a biomarker of proliferative activity. The identification, characterization and measurement of M-protein is essential for the management of MG. We conducted a systematic review of the different tests and measurement methods used in the clinical laboratory for the study of M-protein in serum and urine, the biochemistry and hematology tests necessary for clinical evaluation, and studies in bone marrow, peripheral blood and other tissues. This review included literature published between 2009 and 2022. The paper discusses the main methodological characteristics and limitations, as well as the purpose and clinical value of the different tests used in the diagnosis, prognosis, monitoring and assessment of treatment response in MG. Included are methods for the study of M-protein, namely electrophoresis, measurement of immunoglobulin levels, serum free light chains, immunoglobulin heavy chain/light chain pairs, and mass spectrometry, and for the bone marrow examination, morphological analysis, cytogenetics, molecular techniques, and multiparameter flow cytometry.
Identifiants
pubmed: 37477188
pii: cclm-2023-0326
doi: 10.1515/cclm-2023-0326
doi:
Substances chimiques
Immunoglobulin Light Chains
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2115-2130Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Campo, E, Jaffe, ES, Cook, JR, Quintanilla-Martinez, L, Swerdlow, SH, Anderson, KC, et al.. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 2022;140:1229–53. https://doi.org/10.1182/BLOOD.2022015851 .
doi: 10.1182/BLOOD.2022015851
Alaggio, R, Amador, C, Anagnostopoulos, I, Attygalle, AD, Araujo, IBde O, Berti, E, et al.. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:1720–48. https://doi.org/10.1038/S41375-022-01620-2 .
doi: 10.1038/S41375-022-01620-2
Mullikin, TC, Rajkumar, SV, Dispenzieri, A, Buadi, FK, Lacy, MQ, Lin, Y, et al.. Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 2016;91:473–5. https://doi.org/10.1002/ajh.24319 .
doi: 10.1002/ajh.24319
Manson, GV, Campagnaro, E, Balog, A, Kaplan, D, Sommers, SR, Fu, P, et al.. Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance. Bone Marrow Transplant 2012;47:1212–6. https://doi.org/10.1038/bmt.2011.244 .
doi: 10.1038/bmt.2011.244
Mitus, AJ, Stein, R, Rappeport, JM, Antin, JH, Antin, JH, Weinstein, HJ, et al.. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989;74:2764–8. https://doi.org/10.1182/blood.v74.8.2764.2764 .
doi: 10.1182/blood.v74.8.2764.2764
Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5 .
doi: 10.1016/S1470-2045(14)70442-5
Kyle, RA, Therneau, TM, Rajkumar, SV, Larson, DR, Plevak, MF, Offord, JR, et al.. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9. https://doi.org/10.1056/nejmoa054494 .
doi: 10.1056/nejmoa054494
van de Donk, NWCJ, Palumbo, A, Johnsen, HE, Engelhardt, M, Gay, F, Gregersen, H, et al.. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica 2014;99:984–96. https://doi.org/10.3324/haematol.2013.100552 .
doi: 10.3324/haematol.2013.100552
Kyle, RA, Larson, DR, Therneau, TM, Dispenzieri, A, Kumar, S, Cerhan, JR, et al.. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 2018;378:241–9. https://doi.org/10.1056/nejmoa1709974 .
doi: 10.1056/nejmoa1709974
El-Khoury, H, Lee, DJ, Alberge, JB, Redd, R, Cea-Curry, CJ, Perry, J, et al.. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol 2022;9:e340–9. https://doi.org/10.1016/S2352-3026(22)00069-2 .
doi: 10.1016/S2352-3026(22)00069-2
Palladini, G, Schönland, S, Merlini, G, Milani, P, Jaccard, A, Bridoux, F, et al.. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J 2023;13:19. https://doi.org/10.1038/S41408-023-00789-8 .
doi: 10.1038/S41408-023-00789-8
Sabinot, A, Ghetti, G, Pradelli, L, Bellucci, S, Lausi, A, Palladini, G. State-of-the-art review on AL amyloidosis in Western Countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev 2023;59. https://doi.org/10.1016/J.BLRE.2023.101040 .
doi: 10.1016/J.BLRE.2023.101040
Kyle, RA, Gertz, MA, Witzig, TE, Lust, JA, Lacy, MQ, Dispenzieri, A, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33. https://doi.org/10.4065/78.1.21 .
doi: 10.4065/78.1.21
Landgren, O, Kyle, RA, Pfeiffer, RM, Katzmann, JA, Caporaso, NE, Hayes, RB, et al.. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412–7. https://doi.org/10.1182/blood-2008-12-194241 .
doi: 10.1182/blood-2008-12-194241
Weiss, BM, Abadie, J, Verma, P, Howard, RS, Kuehl, WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418–22. https://doi.org/10.1182/blood-2008-12-195008 .
doi: 10.1182/blood-2008-12-195008
Kyle, RA, Remstein, ED, Therneau, TM, Dispenzieri, A, Kurtin, PJ, Hodnefield, JM, et al.. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–90. https://doi.org/10.1056/NEJMoa070389 .
doi: 10.1056/NEJMoa070389
Leung, N, Bridoux, F, Hutchison, CA, Nasr, SH, Cockwell, P, Fermand, JP, et al.. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120:4292–5. https://doi.org/10.1182/blood-2012-07-445304 .
doi: 10.1182/blood-2012-07-445304
Fermand, JP, Bridoux, F, Dispenzieri, A, Jaccard, A, Kyle, RA, Leung, N, et al.. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018;132:1478–85. https://doi.org/10.1182/blood-2018-04-839480 .
doi: 10.1182/blood-2018-04-839480
Kyle, RA, Durie, BGM, Rajkumar, SV, Landgren, O, Blade, J, Merlini, G, et al.. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7. https://doi.org/10.1038/leu.2010.60 .
doi: 10.1038/leu.2010.60
Mateos, MV, Kumar, S, Dimopoulos, MA, González-Calle, V, Kastritis, E, Hajek, R, et al.. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 2020;10. https://doi.org/10.1038/s41408-020-00366-3 .
doi: 10.1038/s41408-020-00366-3
Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328–46. https://doi.org/10.1016/s1470-2045(16)30206-6 .
doi: 10.1016/s1470-2045(16)30206-6
Owen, RG, Kyle, RA, Stone, MJ, Rawstron, AC, Leblond, V, Merlini, G, et al.. Response assessment in waldenstrom macroglobulinaemia: update from the VIth international workshop. Br J Haematol 2013;160:171–6. https://doi.org/10.1111/bjh.12102 .
doi: 10.1111/bjh.12102
Palladini, G, Dispenzieri, A, Gertz, MA, Kumar, S, Wechalekar, A, Hawkins, PN, et al.. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9. https://doi.org/10.1200/JCO.2011.37.7614 .
doi: 10.1200/JCO.2011.37.7614
Martínez-Brú, C, García-Sanz, R, Martinez-López, J. Recomendaciones para el estudio de las gammapatías monoclonales. Documentos de La SEQC 2009:30–40.
Tate, J, Caldwell, G, Daly, J, Gillis, D, Jenkins, M, Jovanovich, S, et al.. Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Ann Clin Biochem 2012;49:242–56. https://doi.org/10.1258/acb.2011.011158 .
doi: 10.1258/acb.2011.011158
Ma, T, Piao, Z, Jin, S, Kwak, Y. Differential expression of serum proteins in multiple myeloma. Exp Ther Med 2019;17:649–56. https://doi.org/10.3892/etm.2018.7010 .
doi: 10.3892/etm.2018.7010
Dispenzieri, A, Kyle, R, Merlini, G, Miguel, JS, Ludwig, H, Hajek, R, et al.. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24. https://doi.org/10.1038/leu.2008.307 .
doi: 10.1038/leu.2008.307
Seaux, L, Van Houcke, S, Dumoulin, E, Fiers, T, Lecocq, E, Delanghe, JR. Dual-wavelength recording, a simple algorithm to eliminate interferences due to UV-absorbing substances in capillary electrophoresis. Electrophoresis 2014;35:2248–52. https://doi.org/10.1002/elps.201400259 .
doi: 10.1002/elps.201400259
Regeniter, A, Siede, WH. Peaks and tails: evaluation of irregularities in capillary serum protein electrophoresis. Clin Biochem 2018;51:48–55. https://doi.org/10.1016/j.clinbiochem.2017.09.017 .
doi: 10.1016/j.clinbiochem.2017.09.017
Bird, J, Behrens, J, Westin, J, Turesson, I, Drayson, M, Beetham, R, et al.. UK myeloma forum (UKMF) and nordic myeloma study group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22–42. https://doi.org/10.1111/j.1365-2141.2009.07807.x .
doi: 10.1111/j.1365-2141.2009.07807.x
Willrich, MAV, Murray, DL, Kyle, RA. Laboratory testing for monoclonal gammopathies: focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin Biochem 2018;51:38–47. https://doi.org/10.1016/j.clinbiochem.2017.05.001 .
doi: 10.1016/j.clinbiochem.2017.05.001
Aksungar, FB, Ayer, M, Serteser, M, Coskun, A, Unsal, I. A triclonal gammopathy in a relapsing multiple myeloma patient, detected by immunosubtraction method. Ann Clin Biochem 2014;51:606–10. https://doi.org/10.1177/0004563213512801 .
doi: 10.1177/0004563213512801
Smith, J, Raines, G, Schneider, HG. A comparison between high resolution serum protein electrophoresis and screening immunofixation for the detection of monoclonal gammopathies in serum. Clin Chem Lab Med 2018;56:256–63. https://doi.org/10.1515/cclm-2017-0266 .
doi: 10.1515/cclm-2017-0266
Litwin, CM, Anderson, SK, Philips, G, Martins, TB, Jaskowski, TD, Hill, HR. Comparison of capillary zone and immunosubtraction with agarose gel and immunofixation electrophoresis for detecting and identifying monoclonal gammopathies. Am J Clin Pathol 1999;112:411–7. https://doi.org/10.1093/ajcp/112.3.411 .
doi: 10.1093/ajcp/112.3.411
Katzmann, JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30:105–11.
Willrich, MAV, Katzmann, JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med 2016;54:907–19. https://doi.org/10.1515/cclm-2015-0580 .
doi: 10.1515/cclm-2015-0580
Murray, DL, Seningen, JL, Dispenzieri, A, Snyder, MR, Kyle, RA, Rajkumar, SV, et al.. Laboratory persistence and clinical progression of small monoclonal abnormalities. Am J Clin Pathol 2012;138:609–13. https://doi.org/10.1309/AJCPT6OWWMHITA1Y .
doi: 10.1309/AJCPT6OWWMHITA1Y
Vernocchi, A, Longhi, E, Lippi, G, Gelsumini, S. Increased monoclonal components: prevalence in an Italian population of 44 474 outpatients detected by capillary electrophoresis. J Med Biochem 2016;35:50–4. https://doi.org/10.1515/jomb-2015-0007 .
doi: 10.1515/jomb-2015-0007
Jacobs, JFM, Turner, KA, Graziani, MS, Frinack, JL, Ettore, MW, Tate, JR, et al.. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med 2020;58:547–59. https://doi.org/10.1515/cclm-2019-1105 .
doi: 10.1515/cclm-2019-1105
Murata, K, McCash, SI, Carroll, B, Lesokhin, AM, Hassoun, H, Lendvai, N, et al.. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clin Biochem 2018;51:66–71. https://doi.org/10.1016/j.clinbiochem.2016.09.015 .
doi: 10.1016/j.clinbiochem.2016.09.015
McCudden, CR, Voorhees, PM, Hainsworth, SA, Whinna, HC, Chapman, JF, Hammett-Stabler, CA, et al.. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem 2010;56:1897–9. https://doi.org/10.1373/clinchem.2010.152116 .
doi: 10.1373/clinchem.2010.152116
Van De Donk, NWCJ, Otten, HG, El Haddad, O, Axel, A, Sasser, AK, Croockewit, S, et al.. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med 2016;54:1105–9. https://doi.org/10.1515/cclm-2015-0888 .
doi: 10.1515/cclm-2015-0888
Genzen, JR, Murray, DL, Abel, G, Meng, QH, Baltaro, RJ, Rhoads, DD, et al.. Screening and diagnosis of monoclonal gammopathies: an international survey of laboratory practice. Arch Pathol Lab Med 2018;142:507–15. https://doi.org/10.5858/arpa.2017-0128-CP .
doi: 10.5858/arpa.2017-0128-CP
Pérez Surribas, D, Cárdenas Fernández, MC, Zapico Muñiz, D. Recomendaciones sobre la separación electroforética de las proteínas plasmáticas en suero. Recomendación (2014). Documentos de La SEQC 2015:91–104.
Clavijo, A, Ryan, N, Xu, H, Singh, G. Measurement of monoclonal immunoglobulin protein concentration in serum protein electrophoresis: comparison of automated vs. manual/human readings. Lab Med 2020;51:252–8. https://doi.org/10.1093/LABMED/LMZ055 .
doi: 10.1093/LABMED/LMZ055
Turner, KA, Frinack, JL, Ettore, MW, Tate, JR, Graziani, MS, Jacobs, JFM, et al.. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med 2020;58:533–46. https://doi.org/10.1515/cclm-2019-1104 .
doi: 10.1515/cclm-2019-1104
Cárdenas Fernández, MC, Pérez Surribas, D, Pérez Garay, R, Jiménez Jiménez, J, Gella Concustell, A, Zapico Muñiz, E, et al.. Vertical cutoff methods in serum protein electrophoresis for the measurement of monoclonal protein concentrations: which is best? Clin Chim Acta 2020;510:573–80. https://doi.org/10.1016/j.cca.2020.07.051 .
doi: 10.1016/j.cca.2020.07.051
Luraschi, P, Infusino, I, Merlotti, C, Franzini, C. Analytical variation in the measurement of serum monoclonal component by capillary electrophoresis. Clin Chim Acta 2004;349:151–6. https://doi.org/10.1016/j.cccn.2004.06.016 .
doi: 10.1016/j.cccn.2004.06.016
Vallés Díez, I, Fernández-Montes, BG, Cárdenas Fernández, MC, Arroyo Fernández, M. Evaluación de la electroforesis capilar como método de detección y medida de proteína de Bence Jones. Rev. Del Lab. Clin. 2013;6:60–7. https://doi.org/10.1016/j.labcli.2013.01.004 .
doi: 10.1016/j.labcli.2013.01.004
Natali, P, Cigliana, G, Napodano, C, Basile, V, Debbia, D, Pocino, K, et al.. The dark side of current analytic methods for Bence Jones Proteinuria. Eur Rev Med Pharmacol Sci 2022;26:6777–86. https://doi.org/10.26355/EURREV_202209_29779 .
doi: 10.26355/EURREV_202209_29779
Basset, M, Milani, P, Ferretti, VV, Nuvolone, M, Foli, A, Benigna, F, et al.. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. Clin Chem Lab Med 2022;60:386–93. https://doi.org/10.1515/CCLM-2021-0912/PDF .
doi: 10.1515/CCLM-2021-0912/PDF
Murray, DL, Ryu, E, Snyder, MR, Katzmann, JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem 2009;55:1523–9. https://doi.org/10.1373/clinchem.2009.124461 .
doi: 10.1373/clinchem.2009.124461
Milani, P, Palladini, G, Merlini, G. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. Scand J Clin Lab Invest 2016;76:S113–8. https://doi.org/10.1080/00365513.2016.1210337 .
doi: 10.1080/00365513.2016.1210337
Tate, JR. The paraprotein - an enduring biomarker. Clin Biochem Rev 2019;40:5–22.
Rajkumar, SV. Evolving diagnostic criteria for multiple myeloma. Hematology Am Soc Hematol Educ Program 2015;2015:272–8. https://doi.org/10.1182/ASHEDUCATION-2015.1.272 .
doi: 10.1182/ASHEDUCATION-2015.1.272
Keren, DF, Bocsi, G, Billman, BL, Etzell, J, Faix, JD, Kumar, S, et al.. Laboratory detection and initial diagnosis of monoclonal gammopathies: guideline from the college of American pathologists in collaboration with the American association for clinical chemistry and the American society for clinical pathology. Arch Pathol Lab Med 2022;146:575–90. https://doi.org/10.5858/arpa.2020-0794-cp .
doi: 10.5858/arpa.2020-0794-cp
Katzmann, JA. Detection of M proteins. In: Multiple myeloma: diagnosis and treatment . New York: Springer; 2014. 17–26 pp.
Kastritis, E, Zagouri, F, Symeonidis, A, Roussou, M, Sioni, A, Pouli, A, et al.. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia 2014;28:2075–9. https://doi.org/10.1038/leu.2014.110 .
doi: 10.1038/leu.2014.110
Miyazaki, K, Suzuki, K. Abnormal heavy/light chain ratio and matched pair suppression increase residual disease detection sensitivity in patients with multiple myeloma with deep responses. Clin Lymphoma, Myeloma & Leukemia 2018;18:293–6. https://doi.org/10.1016/j.clml.2018.01.008 .
doi: 10.1016/j.clml.2018.01.008
Ríos-Tamayo, R, Puig, N, Algarín, M, García de Veas Silva, JL, Barbosa, N, Encinas, C, et al.. The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: an evidence-based approach. Diagnostics 2021;11:2020. https://doi.org/10.3390/diagnostics11112020 .
doi: 10.3390/diagnostics11112020
Burgos, L, Puig, N, Cedena, MT, Mateos, MV, Lahuerta, JJ, Paiva, B, et al.. Measurable residual disease in multiple myeloma: ready for clinical practice? J Hematol Oncol 2020;13:82. https://doi.org/10.1186/S13045-020-00911-4 .
doi: 10.1186/S13045-020-00911-4
Munshi, NC, Avet-Loiseau, H, Anderson, KC, Neri, P, Paiva, B, Samur, M, et al.. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4:5988–99. https://doi.org/10.1182/bloodadvances.2020002827 .
doi: 10.1182/bloodadvances.2020002827
Paiva, B, Puig, N, Cedena, MT, Rosiñol, L, Cordón, L, Vidriales, MB, et al.. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol 2020;38:784–92. https://doi.org/10.1200/JCO.19.01231 .
doi: 10.1200/JCO.19.01231
Zajec, M, Langerhorst, P, VanDuijn, MM, Gloerich, J, Russcher, H, van Gool, AJ, et al.. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins. Clin Chem 2020;66:421–33. https://doi.org/10.1093/clinchem/hvz041 .
doi: 10.1093/clinchem/hvz041
Murray, D, Barnidge, D. Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory. Crit Rev Clin Lab Sci 2013;50:91–102. https://doi.org/10.3109/10408363.2013.838206 .
doi: 10.3109/10408363.2013.838206
Thoren, KL. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol 2018;55:41–3. https://doi.org/10.1053/j.seminhematol.2018.02.008 .
doi: 10.1053/j.seminhematol.2018.02.008
Mills, JR, Barnidge, DR, Murray, DL. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 2015;81:56–65. https://doi.org/10.1016/j.ymeth.2015.04.020 .
doi: 10.1016/j.ymeth.2015.04.020
Botz, CM, Barnidge, DR, Murray, DL, Katzmann, JA. Detecting monoclonal light chains in urine: MicroLC-ESI-Q-TOF mass spectrometry compared to immunofixation electrophoresis. Br J Haematol 2014;167:437–8. https://doi.org/10.1111/bjh.13003 .
doi: 10.1111/bjh.13003
Mills, JR, Barnidge, DR, Dispenzieri, A, Murray, DL. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J 2017;7:e590. https://doi.org/10.1038/bcj.2017.75 .
doi: 10.1038/bcj.2017.75
Kohlhagen, MC, Barnidge, DR, Mills, JR, Stoner, J, Gurtner, KM, Liptac, AM, et al.. Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016;62:1345–52. https://doi.org/10.1373/clinchem.2015.253781 .
doi: 10.1373/clinchem.2015.253781
Long, S, Qin, Q, Wang, Y, Yang, Y, Wang, Y, Deng, A, et al.. Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma. Talanta 2019;200:288–92. https://doi.org/10.1016/j.talanta.2019.03.067 .
doi: 10.1016/j.talanta.2019.03.067
Milani, P, Murray, DL, Barnidge, DR, Kohlhagen, MC, Mills, JR, Merlini, G, et al.. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol 2017;92:772–9. https://doi.org/10.1002/ajh.24772 .
doi: 10.1002/ajh.24772
Puig, N, Contreras, MT, Agulló, C, Martínez-López, J, Oriol, A, Blanchard, MJ, et al.. Mass spectrometry vs. immunofixation for treatment monitoring in multiple myeloma. Blood Adv 2022;6:3234–9. https://doi.org/10.1182/BLOODADVANCES.2021006762 .
doi: 10.1182/BLOODADVANCES.2021006762
Eveillard, M, Rustad, E, Roshal, M, Zhang, Y, Ciardiello, A, Korde, N, et al.. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br J Haematol 2020;189:904–7. https://doi.org/10.1111/bjh.16443 .
doi: 10.1111/bjh.16443
Mills, JR, Kohlhagen, MC, Willrich, MAV, Kourelis, T, Dispenzieri, A, Murray, DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood 2018;132:670–2. https://doi.org/10.1182/blood-2018-05-848986 .
doi: 10.1182/blood-2018-05-848986
Kourelis, T, Murray, DL, Dasari, S, Kumar, S, Barnidge, D, Madden, B, et al.. MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. Am J Hematol 2018;93:E368–70. https://doi.org/10.1002/ajh.25244 .
doi: 10.1002/ajh.25244
Dispenzieri, A, Larson, DR, Rajkumar, SV, Kyle, RA, Kumar, SK, Kourelis, T, et al.. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia 2020;34:2749–53. https://doi.org/10.1038/s41375-020-0940-8 .
doi: 10.1038/s41375-020-0940-8
Nevone, A, Girelli, M, Mangiacavalli, S, Paiva, B, Milani, P, Cascino, P, et al.. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis. Leukemia 2022;36:2076–85. https://doi.org/10.1038/S41375-022-01599-W .
doi: 10.1038/S41375-022-01599-W
Murray, DL, Puig, N, Kristinsson, S, Usmani, SZ, Dispenzieri, A, Bianchi, G, et al.. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report. Blood Cancer J 2021;11:24. https://doi.org/10.1038/s41408-021-00408-4 .
doi: 10.1038/s41408-021-00408-4
Sargur, R, White, P, Egner, W. Cryoglobulin evaluation: best practice? Ann Clin Biochem 2010;47:8–16.
Ravi, P, Kumar, S, Larsen, JT, Gonsalves, W, Buadi, F, Lacy, MQ, et al.. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016;6:e454.
Murthy, HS, Sheets, K, Kumar, A, Nishihori, T, Mina, A, Chavez, JC, et al.. Hypoalbuminemia at day +90 is associated with inferior nonrelapse mortality and overall survival in allogeneic hematopoietic cell transplantation recipients: a Confirmatory study. Biology of Blood and Marrow Transplantation 2018;24:400–5.
Bender, LM, Cotten, SW, Fedoriw, Y, Willis, MS, McCudden, CR. Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation. Clin Biochem 2013;46:255–8.
Greipp, PR, Miguel, JS, Dune, BGM, Crowley, JJ, Barlogie, B, Bladé, J, et al.. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.
Harousseau, JL, Dreyling, M. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009;20.
Bladé, J, Dimopoulos, M, Rosiñol, L, Rajkumar, SV, Kyle, RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. Journal of Clinical Oncology 2010;28:690–7.
Palumbo, A, Avet-Loiseau, H, Oliva, S, Lokhorst, HM, Goldschmidt, H, Rosinol, L, et al.. Revised international staging system for multiple myeloma: a report from international myeloma working group. Journal of Clinical Oncology 2015;33:2863–9.
Pratt, G, El-Sharkawi, D, Kothari, J, D’Sa, S, Auer, R, McCarthy, H, et al.. Diagnosis and management of waldenström macroglobulinaemia—a British society for haematology guideline. Br J Haematol 2022;197:171–87. https://doi.org/10.1111/bjh.18036 .
doi: 10.1111/bjh.18036
Gertz, MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 2021;96:258–69. https://doi.org/10.1002/ajh.26082 .
doi: 10.1002/ajh.26082
Rajkumar, SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 2018;93:1091–110. https://doi.org/10.1002/ajh.25117 .
doi: 10.1002/ajh.25117
Medina, A, Jiménez, C, Sarasquete, ME, González, M, Chillón, MC, Balanzategui, A, et al.. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer J 2020;10:14. https://doi.org/10.1038/s41408-020-0283-8 .
doi: 10.1038/s41408-020-0283-8
Walker, BA, Boyle, EM, Wardell, CP, Murison, A, Begum, DB, Dahir, NM, et al.. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 2015;33:3911–20. https://doi.org/10.1200/JCO.2014.59.1503 .
doi: 10.1200/JCO.2014.59.1503
Ashby, C, Tytarenko, RG, Wang, Y, Weinhold, N, Johnson, SK, Bauer, M, et al.. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget 2019;10:732–7. https://doi.org/10.18632/oncotarget.26589 .
doi: 10.18632/oncotarget.26589
Alcoceba, M, García-álvarez, M, Medina, A, Maldonado, R, González-Calle, V, Chillón, MC, et al.. MYD88 mutations: transforming the landscape of IgM monoclonal gammopathies. Int J Mol Sci 2022;23:5570. https://doi.org/10.3390/IJMS23105570 .
doi: 10.3390/IJMS23105570
Kuiper, R, Van Duin, M, Van Vliet, MH, Broijl, A, Van Der Holt, B, Jarari, LE, et al.. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015;126:1996–2004. https://doi.org/10.1182/BLOOD-2015-05-644039 .
doi: 10.1182/BLOOD-2015-05-644039
Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al.. WHO classification of tumours of haematopoietic and lymphoid tissues , 4th ed. Lyon: International Agency for Research on Cancer; 2017.
Kroft, SH, Harrington, AM. Flow cytometry of B-cell neoplasms. Clin Lab Med 2017;37:697–723. https://doi.org/10.1016/j.cll.2017.07.001 .
doi: 10.1016/j.cll.2017.07.001
Paiva, B, Montes, MC, García-Sanz, R, Ocio, EM, Alonso, J, De Las Heras, N, et al.. Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 2014;28:166–73. https://doi.org/10.1038/leu.2013.124 .
doi: 10.1038/leu.2013.124
Gascue, A, Merino, J, Paiva, B. Flow cytometry. Hematol Oncol Clin N Am 2018;32:765–75. https://doi.org/10.1016/j.hoc.2018.05.004 .
doi: 10.1016/j.hoc.2018.05.004
Puig, N, Paiva, B, Lasa, M, Burgos, L, Perez, JJ, Merino, J, et al.. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia 2019;33:1256–67. https://doi.org/10.1038/s41375-018-0308-5 .
doi: 10.1038/s41375-018-0308-5
Paiva, B, Chandia, M, Vidriales, MB, Colado, E, Caballero-Velázquez, T, Escalante, F, et al.. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood 2014;124:1300–3. https://doi.org/10.1182/blood-2014-04-567909 .
doi: 10.1182/blood-2014-04-567909
Paiva, B, Almeida, J, Pérez-Andrés, M, Mateo, G, López, A, Rasillo, A, et al.. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytometry 2010;78:239–52. https://doi.org/10.1002/cyto.b.20512 .
doi: 10.1002/cyto.b.20512
Van Dongen JJM, Lhermitte, L, Böttcher, S, Almeida, J, Van Der Velden, VHJ, Flores-Montero, J, et al.. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908–75. https://doi.org/10.1038/leu.2012.120 .
doi: 10.1038/leu.2012.120
Flores-Montero, J, de Tute, R, Paiva, B, Perez, JJ, Böttcher, S, Wind, H, et al.. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytometry 2016;90:61–72. https://doi.org/10.1002/cyto.b.21265 .
doi: 10.1002/cyto.b.21265
Soh, KT, Tario, JD, Wallace, PK. Diagnosis of plasma cell dyscrasias and monitoring of minimal residual disease by multiparametric flow cytometry. Clin Lab Med 2017;37:821–53. https://doi.org/10.1016/j.cll.2017.08.001 .
doi: 10.1016/j.cll.2017.08.001
Paiva, B, Vidriales, MB, Pérez, JJ, Mateo, G, Montalbán, MA, Mateos, MV, et al.. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009;94:1599–602. https://doi.org/10.3324/haematol.2009.009100 .
doi: 10.3324/haematol.2009.009100
Pérez-Persona, E, Mateo, G, García-Sanz, R, Mateos, MV, De Las Heras, N, De Coca, AG, et al.. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010;148:110–4. https://doi.org/10.1111/j.1365-2141.2009.07929.x .
doi: 10.1111/j.1365-2141.2009.07929.x
Burgos, L, Tamariz-Amador, L-E, Puig, N, Cedena, M-T, Guerrero, C, Jelínek, T, et al.. Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies. J Clin Oncol 2023;41:3019–31. https://doi.org/10.1200/JCO.22.01916 .
doi: 10.1200/JCO.22.01916
Mateo, G, Montalbán, MA, Vidriales, MB, Lahuerta, JJ, Mateos, MV, Gutiérrez, N, et al.. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737–44. https://doi.org/10.1200/JCO.2007.15.4120 .
doi: 10.1200/JCO.2007.15.4120
Paiva, B, Gutierrez, NC, Chen, X, Vidriales, MB, Montalban, MA, Rosinol, L, et al.. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 2012;26:1862–9. https://doi.org/10.1038/leu.2012.42 .
doi: 10.1038/leu.2012.42
Kastritis, E, Kostopoulos, IV, Terpos, E, Paiva, B, Fotiou, D, Gavriatopoulou, M, et al.. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J 2018;8:46. https://doi.org/10.1038/s41408-018-0086-3 .
doi: 10.1038/s41408-018-0086-3
Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, et al.. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31:2094–103. https://doi.org/10.1038/leu.2017.29 .
doi: 10.1038/leu.2017.29
Medina, A, Puig, N, Flores-Montero, J, Jimenez, C, Sarasquete, ME, Garcia-Alvarez, M, et al.. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J 2020;10:108. https://doi.org/10.1038/s41408-020-00377-0 .
doi: 10.1038/s41408-020-00377-0
Paiva, B, Martinez-Lopez, J, Vidriales, MB, Mateos, MV, Montalban, MA, Fernandez-Redondo, E, et al.. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29:1627–33. https://doi.org/10.1200/JCO.2010.33.1967 .
doi: 10.1200/JCO.2010.33.1967
Jiménez-Ubieto, A, Paiva, B, Puig, N, Cedena, MT, Martínez-López, J, Oriol, A, et al.. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change? Blood 2021;138:1901–5. https://doi.org/10.1182/blood.2021012319 .
doi: 10.1182/blood.2021012319
Tschautscher, M, Jevremovic, D, Buadi, FK, Lacy, MQ, Gertz, MA, Dispenzieri, A, et al.. Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Am J Hematol 2020;95:E60–2. https://doi.org/10.1002/ajh.25702 .
doi: 10.1002/ajh.25702
Terpos, E, Kostopoulos, IV, Kastritis, E, Ntanasis-Stathopoulos, I, Migkou, M, Rousakis, P, et al.. Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy. Hemasphere 2019;3:1. https://doi.org/10.1097/HS9.0000000000000300 .
doi: 10.1097/HS9.0000000000000300
Puig, N, Flores-Montero, J, Burgos, L, Cedena, MT, Cordón, L, Pérez, JJ, et al.. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma. Cancers 2021;13:4924. https://doi.org/10.3390/CANCERS13194924 .
doi: 10.3390/CANCERS13194924
Tschautscher, MA, Jevremovic, D, Rajkumar, V, Dispenzieri, A, Lacy, MQ, Gertz, MA, et al.. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am J Hematol 2019;94:751–6. https://doi.org/10.1002/AJH.25481 .
doi: 10.1002/AJH.25481
Pojero, F, Casuccio, A, Giambanco, C, Bulati, M, Buffa, S, Di Bassiano, F, et al.. Bone marrow B lymphocytes in multiple myeloma and MGUS: focus on distribution of naïve cells and memory subsets. Leuk Res 2016;49:51–9. https://doi.org/10.1016/j.leukres.2016.08.008 .
doi: 10.1016/j.leukres.2016.08.008
Sanoja-Flores, L, Flores-Montero, J, Pérez-Andrés, M, Puig, N, Orfao, A. Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications. Cancers 2020;12:1–26. https://doi.org/10.3390/cancers12061499 .
doi: 10.3390/cancers12061499
Levin, A, Hari, P, Dhakal, B. Novel biomarkers in multiple myeloma. Transl Res 2018;201:49–59. https://doi.org/10.1016/j.trsl.2018.05.003 .
doi: 10.1016/j.trsl.2018.05.003
Sanoja-Flores, L, Flores-Montero, J, Garcés, JJ, Paiva, B, Puig, N, García-Mateo, A, et al.. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018;8:117. https://doi.org/10.1038/s41408-018-0153-9 .
doi: 10.1038/s41408-018-0153-9
Gonsalves, WI, Jevremovic, D, Nandakumar, B, Dispenzieri, A, Buadi, FK, Dingli, D, et al.. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol 2020;95:310–5. https://doi.org/10.1002/ajh.25709 .
doi: 10.1002/ajh.25709
Bae, MH, Park, CJ, Kim, BH, Cho, YU, Jang, S, Lee, DH, et al.. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma. Cytometry B Clin Cytometry 2018;94:493–9. https://doi.org/10.1002/cyto.b.21606 .
doi: 10.1002/cyto.b.21606
Sidana, S, Tandon, N, Dispenzieri, A, Gertz, MA, Dingli, D, Jevremovic, D, et al.. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia 2018;32:1421–6. https://doi.org/10.1038/S41375-018-0063-7 .
doi: 10.1038/S41375-018-0063-7
Gonsalves, WI, Rajkumar, SV, Gupta, V, Morice, WG, Timm, MM, Singh, PP, et al.. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 2014;28:2060–5. https://doi.org/10.1038/leu.2014.98 .
doi: 10.1038/leu.2014.98
Sanoja-Flores, L, Flores-Montero, J, Puig, N, Contreras-Sanfeliciano, T, Pontes, R, Corral-Mateos, A, et al.. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood 2019;134:2218–22. https://doi.org/10.1182/blood.2019002610 .
doi: 10.1182/blood.2019002610
Fernández de Larrea, C, Kyle, R, Rosiñol, L, Paiva, B, Engelhardt, M, Usmani, S, et al.. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 2021;11:192. https://doi.org/10.1038/S41408-021-00587-0 .
doi: 10.1038/S41408-021-00587-0
Jelinek, T, Bezdekova, R, Zihala, D, Sevcikova, T, Sithara, AA, Pospisilova, L, et al.. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol 2023;41:1383–92. https://doi.org/10.1200/JCO.22.01226 .
doi: 10.1200/JCO.22.01226
López-Anglada, L, Gutiérrez, NC, García, JL, Mateos, MV, Flores, T, San Miguel, JF. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol 2010;84:359–61. https://doi.org/10.1111/j.1600-0609.2009.01399.x .
doi: 10.1111/j.1600-0609.2009.01399.x
Katodritou, E, Kastritis, E, Gatt, M, Cohen, YC, Avivi, I, Pouli, A, et al.. Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: a study of the Greco-Israeli collaborative myeloma working group. Am J Hematol 2020;95:465–71. https://doi.org/10.1002/ajh.25755 .
doi: 10.1002/ajh.25755
Dispenzieri, A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program 2020;2020:380–8. https://doi.org/10.1182/HEMATOLOGY.2020000122 .
doi: 10.1182/HEMATOLOGY.2020000122